Drug Profile
REP 2165
Alternative Names: REP 2165 magnesium chelate; REP 2165-MgLatest Information Update: 23 Mar 2023
Price :
$50
*
At a glance
- Originator REPLICor
- Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
- Mechanism of Action Hepatitis B virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B; Hepatitis D
Most Recent Events
- 23 Mar 2023 Discontinued - Phase-II for Hepatitis B (Combination therapy, Treatment-naive) in Moldova (IV)
- 23 Mar 2023 Discontinued - Preclinical for Hepatitis D in Canada (IV)
- 12 Nov 2021 Additional efficacy data from the IIb REP 401 trial in Hepatitis B presented at the The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases AASLD-2021